Trials / Completed
CompletedNCT06984159
The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart.
An Open-Label, Single-Arm, Multicenter Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Leuprolide Injectable Emulsion in Advanced Prostate Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 137 (actual)
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the Safety, Efficacy and Pharmacokinetics of Leuprolide Injectable Emulsion in Advanced Prostate Cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Leuprolide Injectable Emulsion (CAMCEVI®) | Leuprolide Injectable Emulsion (CAMCEVI®)，Subcutaneous injection，Once every 24 weeks for a total of 2 doses |
Timeline
- Start date
- 2022-07-12
- Primary completion
- 2023-11-30
- Completion
- 2024-04-24
- First posted
- 2025-05-22
- Last updated
- 2025-05-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06984159. Inclusion in this directory is not an endorsement.